MedDay Pharmaceuticals SA
11
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
27.3%
3 terminated/withdrawn out of 11 trials
57.1%
-29.4% vs industry average
27%
3 trials in Phase 3/4
75%
3 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Role: lead
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Role: lead
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects
Role: lead
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
Role: lead
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
Role: lead
TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
Role: lead
Effect of MD1003 in Amyotrophic Lateral Sclerosis
Role: lead
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
Role: collaborator
MD1003-AMN MD1003 in Adrenomyeloneuropathy
Role: lead
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
Role: lead
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
Role: lead
All 11 trials loaded